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Abstract
Diagnostic testing for malaria has for many years been eschewed, lest it be an obstacle to the
delivery of rapid, life-saving treatment. The approach of treating malaria without confirmatory
testing has been reinforced by the availability of inexpensive treatment with few side effects, by the
great difficulty of establishing quality-assured microscopy in rural and resource-poor settings, and
by the preeminence of malaria as a cause of important fever in endemic regions. Within the last
decade, all three of these factors have changed. More expensive artemisinin combination therapy
(ACT) has been widely introduced, simple immunochromatographic tests for malaria have been
developed that can be used as an alternative to microscopy by village health workers, and
recognition of the health cost of mismanaging non-malarial fever is growing. In most of the world
a small fraction of fever is due to malaria, and reflex treatment with ACT does not make medical
or economic sense. Global malaria control efforts have been energized by the availability of new
sources of funding, and by the rapid reduction in malaria prevalence in a number of settings where
bed nets, indoor residual spraying with insecticides, and ACT have been systematically deployed.
This momentum has been captured by a new call for malaria elimination. Without wide
implementation of accurate and discriminating diagnostic testing, and reporting of results, most
fever will be inappropriately managed, millions of doses of ACT will be wasted, and malaria control
programmes will be blindfolded to the impact of their efforts.
Introduction
Malaria control has recently seen a long-overdue resur-
gence in interest and funding, a belated recognition that
malaria is still dominating the lives and health of mil-
lions, and holding whole populations in poverty. In
places where these renewed efforts have been systemati-
cally applied, insecticide-treated bed nets, indoor residual
spraying, and artemisinin-based combination therapy
(ACT) have demonstrated their capacity to reduce both
incidence and mortality from malaria. For the first time in
decades, the idea of elimination of malaria as a public
health problem, and perhaps complete interruption of
transmission across whole regions, is being considered.
However, although modern prevention and treatment
tools for malaria are shown to be effective, long-term suc-
cess in controlling malaria, and in reducing the morbidity
and mortality of fever in the tropics, will require a funda-
mental change in the way fever is managed, and in the
specificity with which malaria care is allocated. This article
argues that the role of diagnosis must be prioritized, both
for case management and for surveillance, and that
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progress toward malaria elimination will only increase the
need for good diagnostic information.
Background
Most causes of fever in the tropics are transient, non-fatal
illnesses. In the latter half of the 19th century, it was dis-
covered that many of the infectious causes of fever that
did have the potential to be fatal, including malaria, leish-
maniasis, tuberculosis, sleeping sickness and others, were
detectable by microscopy. For one of these, malaria, there
was a relatively early pharmacological intervention thanks
to the long history of quinine (cinchona) use in the Amer-
icas. The utility of microscopy in tropical fevers, and the
availability of life-saving treatment for malaria, led to the
wide advocacy of microscopy-based case management as
the standard of care. When microscopy was found to be
untenable in many parts of the world, due to the massive
effort and resources required to maintain such a service in
close proximity to the rural and poor populations widely
at risk, syndromic management, classifying all 'malaria-
like' fevers as malaria, again became the de facto standard
of practice.
For the last three quarters of a century then, since the dis-
covery and development of chloroquine in the 1930s and
40s, the medical community has treated most fevers in
malaria-endemic countries as malaria, forgoing the diag-
nostic process. This practice has been codified into
national and international recommendations and train-
ing manuals for health workers, especially for fever in chil-
dren. The common teaching has been 'fever equals
malaria unless proven otherwise'.
Clearly many lives have been saved by pushing for rapid,
even community or home-based access to antimalarial
therapy, regardless of diagnostic testing. In the many com-
munities in which malaria has accounted for the majority
of potentially fatal causes of fever, it has been hard to
imagine any other approach, given the poor performance
and relative unavailability of microscopy [1-6].
Over the past decade, though, a number of important
changes have taken place in the epidemiology and control
of malaria and in the diagnostic techniques available, that
dramatically alter the balance of rational action in favour
of parasite-based diagnosis over blind therapy of fever
with anti-malarial drugs. Specific diagnosis of malaria is
now not only possible, but necessary, and scaled up
malaria control efforts, including elimination plans, must
include expanded and quality assured use of parasite-
based diagnostic testing and reporting of results.
Overdiagnosis of malaria and fever mismanagement
Unfortunately, the clinical presentation of malaria is
highly variable and overlaps with that of a number of
other common illnesses, including pneumonia, which are
associated with significant morbidity and mortality [7,8].
Attempts to develop clinical scoring systems with high
predictive values have largely been unsuccessful [9-12],
and health workers without access to tools for parasite-
based diagnosis often manage most or all fevers as
malaria. This practice continues to be included in medical
training and in national treatment guidelines [13]. As
summarized by Amexo and colleagues [14], however, pre-
sumptive management of fever as malaria results in signif-
icant overdiagnosis, even in high-risk areas. In many
settings, especially where malaria is seasonal or where
intensive disease control efforts are implemented, a small
minority of febrile patients may be parasitaemic [15-18].
The 2008 World Malaria Report estimates well below a
third of fevers in endemic areas of Africa are due to
malaria, and much less again in other regions. In India,
for instance, slide positivity rates, based on approximately
100 million slides examined, are about 2% [18]. Even
when WHO criteria for severe malaria are met, an impor-
tant fraction of patients may be found to have an alterna-
tive cause of fever on post-mortem or other careful
investigation [19,20]. Unfortunately, not enough is
known about the causes of non-malarial fevers in the
tropics.
During a period when inexpensive drugs such as chloro-
quine were available, widespread overtreatment for
malaria was accepted as a means to improve treatment
coverage and decrease mortality. With rising drug resist-
ance, national malaria control programmes are moving to
more expensive and more effective artemisinin combina-
tion therapy (ACT), and the cost of drugs wasted on treat-
ment of non-malarial fever become substantial.
Malaria misdiagnosis and subsequent mis-management
has individual as well as societal repercussions. At the
individual level, misdiagnosis results in wasted resources
on drug purchase, especially in the private sector, expo-
sure to drug side effects, and most importantly morbidity
due to improper management of the true cause of fever.
Early treatment with effective drugs is vital in acute respi-
ratory tract infections, meningitis, and other differential
diagnoses of malaria, in the same way that early, appropri-
ate and effective treatment is fundamental to reducing
malaria case fatality rates (Figure 1) [21]. Due to the cost
of drugs and of complications from inappropriately man-
aged illness, and to the limitations in access to good
microscopy services in remote and resource-poor loca-
tions, impoverished individuals are disproportionately
affected by malaria misdiagnosis [14]. At a societal level,
mismanagement of fever erodes patient's faith in the
health system, wastes drug resources, augments drug pres-
sure toward resistance [22], and contributes to ignorance
of the true causes of illness in these populations. In theMalaria Journal 2008, 7(Suppl 1):S5 http://www.malariajournal.com/content/7/S1/S5
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face of this, it should be disturbing that less than 20% of
suspected malaria cases receive a confirmatory diagnosis
in 75% of African countries [18].
One of the drivers of presumptive treatment is fear of
rapid mortality of untreated malaria, especially in young
children. Increasing evidence suggests that where accurate
parasite-based diagnosis is present, febrile children with
negative malaria examinations may safely be cared for
without antimalarial treatment [23,24]. A carefully per-
formed study in Uganda examined whether, in a setting of
low to moderate transmission, microscopy-directed ther-
apy would result in excess mortality from unrecognized
and untreated malaria. Of 2,359 medical visits by children
<10 years of age presenting with fever, 1,608 (68%) were
microscopy-negative and were not given anti-malarial
drugs. During seven days of follow-up, only 13 (0.8%)
were subsequently diagnosed with malaria. There were no
deaths, and no episodes of severe malaria [15]. Similarly,
Ngasala and colleagues found that microscopy-based
treatment was safe and effective in children under five
years old, even where less expert microscopy was used for
screening [25]. Modeling studies suggest that even at high
parasite prevalence the benefits of improved management
of non-malarial illness make parasite-based diagnostic
methods cost-effective [26]. WHO is currently developing
evidence-based recommendations in this area.
Development of rapid diagnostic tests (RDTs)
Microscopy services for the diagnosis of malaria are not
widely available, especially at the community level where
most urgent care takes place. Microscopy infrastructure is
cumbersome to develop, requires trained and motivated
staff, well-maintained equipment, and a well-executed
quality assurance system. In the hands of many micro-
scopists in low-income settings where training, equip-
ment and reagents may be substandard, the accuracy of
microscopy is poor [1-6]. A 2006 study in Kenya found
routine microscopy to be only 69% sensitive and 62%
specific when compared with expert microscopy [3].
While standards vary and microscopy remains invaluable
for diagnosis, parasite quantitation and treatment moni-
toring where good standards can be maintained, ensuring
the quality of microscopy as a system-wide approach has
proved beyond the capability of most malaria control pro-
grammes.
High mortality at 10 Tanzanian hospitals among patients admitted with severe disease and treated for malaria Figure 1
High mortality at 10 Tanzanian hospitals among patients admitted with severe disease and treated for malaria. (Adapted from 
[22]).
Admissions for malaria n=17,313 
Severe disease n=4670 (27%) 
Readable slide results n=4474 (95%) 
No criteria for 
severe disease  
n=12,643 (73%) 
120 deaths (1%) 
Expert microscopy negative
n=2412 (54%) 
Dead 
n=142 (7%) 
Alive 
n=1920 (93%)
Dead 
n=292 (12%) 
Alive 
n=2120 (88%) 
Expert microscopy positive 
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For these reasons the development, in the early 1990s, of
lateral flow immunochromatographic tests that could
detect malaria parasite antigens in a fingerprick blood
sample was a major advance [27,28]. These rapid diagnos-
tic tests (RDT) are based on the ability of monoclonal
antibodies to bind to parasite antigens in lysed blood and
immobilize them along a defined line on nitrocellulose
for detection with a colored label (most commonly colloi-
dal gold). All existing commercial RDTs target one or
more of well characterized Plasmodium protein targets:
histidine rich protein 2 (HRP2), parasite lactate dehydro-
genase (pLDH), or aldolase (see Table 1). HRP2 is present
in Plasmodium falciparum only, whereas pLDH and aldo-
lase, with some conserved and some variable epitopes, are
present in all four major species causing human malaria.
RDTs have the obvious advantage of requiring less train-
ing, being easily performed in remote or village settings,
and putting most of the quality control responsibility in
the hands of the manufacturer instead of the user.
These tests are in relatively wide use in many South Amer-
ican and Asian countries, where use has been scaled up, as
seen in Figure 2 below from India, to accompany ACT
[29]. Use is now increasing in a number of African coun-
tries, such as Ethiopia, Zambia, Uganda and Nigeria, after
specific allocation of funds for RDT purchase in proposals
to the Global Fund Against AIDS, TB, and Malaria
(GFATM) and other funding sources. Global sales of
malaria RDTs are thought to surpass 70 million tests a
year. From a single manufacturer in 1993, there are now
dozens of diagnostics companies manufacturing or re-
branding malaria RDTs. There are several sources of mon-
oclonal antibodies against the common antigen targets,
and companies making lateral flow tests for other indica-
tions such as pregnancy testing, screening for illicit drugs
Table 1: Target antigen combinations in commercially available RDTs. Adapted from [34].
RDT type Target antigens Possible results
IH R P 2 N o  P f
Pf
Invalid
II HRP2 No malaria
Aldolase (all species) Pf or mixed
Pv, Po, and/or Pm
Invalid
III HRP2 No malaria
pLDH (all species) Pf or mixed
Pv, Po, and/or Pm
Invalid
IV pLDH (falciparum-specific) No malaria
pLDH (all species) Pf or mixed
Invalid
V pLDH (falciparum-specific) No malaria
pLDH (vivax-specific) Pf
Pv
Pf + Pv
Invalid
VI HRP2 No malaria
pLDH (falciparum-specific) Pf or mixed
pLDH (vivax-specific) Pf + Pv, +/- Po and/or Pm
Pf +/- Po and/or Pm
Pv +/- Po and/or Pm
Po and/or Pm
Invalid
VII Aldolase (all species) No malaria
Pf, Pv, Po and/or Pm
InvalidMalaria Journal 2008, 7(Suppl 1):S5 http://www.malariajournal.com/content/7/S1/S5
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or diagnosis of infectious diseases can, without much dif-
ficulty or expense, add malaria to their test portfolio.
The profusion of malaria test manufacturers, many of
them small, combined with their difficulty obtaining ref-
erence clinical materials from well-characterized malaria
patients and the lack of biologic reference standards, has
resulted in significant variability in the quality of tests
being manufactured. Dozens of diagnostic trials of RDT
performance have been carried out, and several reviews
published [30-33]. Variability in trial design, in popula-
tion selection, in reference methods, and in handling and
storage of the RDTs make it difficult to draw robust con-
clusions about the performance and accuracy of specific
RDTs tested in these studies, and impossible to distin-
guish between potential problems with the quality of the
tests themselves and factors specific to the trial.
Many RDTs have been shown to perform well, detecting
over 90% of malaria cases, including those with relatively
low parasite density (200 parasites/μl). Several RDTs dis-
tinguish between falciparum and non-falciparum malaria,
and in ideal conditions bring the power of reliable expert
microscopy (detection, species identification, and to a
much lesser extent, quantitation) and put it in the hands
of village health workers. Unfortunately, though these
tests have been shown to be useful, cost-effective [26], and
safe in the direction of antimalarial therapy [23,24],
health care workers frequently ignore results, either
because of ingrained treatment habits, pressure to treat
from patients and family members, or doubt about the
accuracy of the RDT results [16]. Clearly, if RDTs are going
to shift the global paradigm of fever management from
reflex antimalarial treatment to diagnostic-directed treat-
ment, systems will need to be in place to: 1) ensure the
confidence of the health worker in the performance of the
diagnostic test [34], and 2) provide capacity to appropri-
ately and effectively manage the illnesses of RDT-negative
patients [14,35].
Assuring the quality of malaria RDTs
Over the past several years, a three-pronged programme of
quality assurance for malaria RDTs being used in the pub-
lic sector has been put in place. Led by WHO, FIND
(Foundation for Innovative New Diagnostics) and multi-
ple partners, these activities are intended to address uncer-
tainties both about the quality of manufacture as well as
the stability and performance of RDTs post-purchase.
One part of this programme involves assembling a
restricted list of high-quality rapid tests for purchase
through the public sector. To be on this list, tests must be
manufactured under ISO-13485:2003 certification and
must show good performance when tested against a panel
of reference materials. To evaluate performance, a bank of
highly characterized reference materials has been estab-
lished at the US CDC that contains cultured parasites,
recombinant proteins, and large numbers of aliquots of
blood from malaria-infected patients whose blood is col-
lected under protocol and then diluted to fixed and clini-
cally-relevant concentrations of parasites. Results from the
first round of this testing should be available in January
2009, and are expected to direct public sector purchasing
toward only those tests showing good performance and
temperature stability.
A second part of the QA programme allows countries or
agencies purchasing RDTs for public sector use to submit
samples of purchased lots for testing after arrival of the
products. This ensures both that the lot purchased meets
performance and quality standards, and that the tests
maintained accuracy despite temperature and humidity
stresses encountered during shipment [36]. With this
capacity now in place, there is no reason that sub-standard
batches of RDTs should now be delivered to health work-
ers in the field.
The third arm of the WHO/FIND QA process for RDTs is
to create positive control wells (PCW), composed of
recombinant antigens at concentrations intended to give
a weak-positive result, that should allow the village health
worker or other care provider to test an RDT from any box
before use, ensuring that the kit has not degraded during
storage and transport, and bolstering confidence that the
results of testing may be used to direct therapy. This devel-
opment promises to greatly improve on the current neces-
sity to perform comparative microscopy at sentinel sites to
monitor RDT field performance. Prototype PCWs,
designed for long-term stability, will be evaluated in field
studies in the first quarter of 2009.
Scaled-up use of ACT and RDTs in India, in millions Figure 2
Scaled-up use of ACT and RDTs in India, in millions.
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Diagnostics in the malaria elimination campaign
Now 40 years after the failure of the first Global Malaria
Eradication Campaign [37], there are new calls for malaria
elimination, and in a few settings advanced degrees of
control have already been accomplished. At the recent
2008 Millennium Development Goals Malaria Summit,
an ambitious new Global Malaria Action Plan was
endorsed and nearly $3 billion committed towards reduc-
ing the number of malaria deaths to near zero by 2015.
A drive towards malaria elimination will increase the need
for broad use of quality assured diagnostics for malaria,
and possibly the development of novel assays to address
specific needs such as the sensitivity at low parasite densi-
ties and minimal invasiveness required for population-
based surveys for parasite reservoirs. The imperative for
parasitologic diagnosis will be dramatically increased
where malaria incidence falls, and where reflex treatment
of fever with antimalarial drugs would be ineffective and
even harmful in the vast majority of cases.
More important perhaps, is the role of routine malaria
testing as a surveillance method. Mapping malarial cases
will be critical to understanding the effectiveness and
impact of different control policies that are being imple-
mented. Though this is currently done through testing at
sentinel sites or in large population-based surveys, much
more accurate and real-time information can be gathered
through the development of reporting systems that cap-
ture the results of RDT testing at village level. Currently,
very few RDT results are recorded and transmitted back to
centralized levels of the health system in a way that could
serve surveillance needs. For both HIV and tuberculosis,
relatively robust systems are in place that capture the
results of testing in peripheral settings and establish the
basis for national reporting. Though this will be a greater
challenge for malaria, recent developments, including the
existence of RDTs, the strengthening of malaria services
with a rapid increase in funding, and the drive toward
elimination, make such planning feasible. System-wide
reporting would also highlight outbreaks, and could serve
as early harbinger of emerging drug resistance or increased
insecticide resistance in mosquitoes. Elimination plan-
ning and monitoring will require faster and more accurate
information about the incidence and distribution of dis-
ease than is currently available (Figure 3).
Ultimately, the Global Malaria Eradication Campaign
died in the 1960s from donor fatigue. Elimination cam-
paigns are costly and difficult, even when highly effective
tools are available. Without clear and detailed evidence of
the impact of donor spending on malaria case rates and
geographic distribution, donors cannot be expected to
continue to fund control campaigns. The Global Polio
Eradication Initiative, spearheaded by WHO, Rotary Inter-
national, the US CDC and UNICEF, has spent more
money since it missed its goal of eradicating polio by the
year 2000 than in the years leading up to that milestone.
Such support would not have been possible without the
kind of incidence mapping, such as that shown in Figure
3b, that gives donors and public health planners the infor-
mation they need to be assured that the strategy employed
is making an impact, and has clearly defined goals.
New diagnostics
It is likely that if success in malaria control is obtained, it
will lead to the need for, and development of, new diag-
nostic tests. Much of the large public sector market for
malaria RDTs is served by tests that detect only P. falci-
parum, especially in Africa. Despite limitations due to anti-
gen persistence after parasite death [38-40], and target
antigen variability [41], tests detecting only HRP2 from P.
falciparum are most commonly procured, as they are gen-
erally less expensive, may be more stable across tempera-
ture extremes [42], and tend to have a lower threshold of
detection [43]. Detection of P. falciparum will guide treat-
ment for cases most likely to progress to severe disease,
and mono-infections with non-P. falciparum species are
uncommon in much of sub-Saharan Africa. As ACTs are
increasingly used, however, it is likely that non-falci-
parum malaria will form an ever-greater fraction of cases.
This is already true in parts of Ethiopia, where the conven-
tional ratio of 70/30 falciparum/non-falciparum recently
reversed in some areas of the country. Public sector
deployment of RDTs in Africa may increasingly shift away
from falciparum-only tests. Ongoing research aims to
develop more stable tests that allow species differentia-
tion, against either the current targets or novel target anti-
gens.
The sensitivity of tests for malaria may need to higher in
areas where good malaria control is being effected than
current testing allows. Microscopy and RDTs both become
relatively insensitive at parasite densities below 100 para-
sites/μl. PCR studies have shown that low-level parasitae-
mia missed by RDTs and conventional microscopy can be
uncovered with sensitive molecular methods. As individ-
uals with low-level parasitaemia may act as reservoirs for
transmission, their detection may be necessary to acceler-
ate elimination. Various groups are working on the devel-
opment of potentially highly sensitive assays that may be
used in peripheral laboratories for detection of falciparum
and non-falciparum malaria [44-46]. To eliminate
malaria in areas with significant transmission of P. vivax
or P. ovale, tests may also be required that detect hypno-
zoites to guide the use of 8-aminoquinolones (pri-
maquine, terbinafine) that clear these liver stages and
prevent relapse.Malaria Journal 2008, 7(Suppl 1):S5 http://www.malariajournal.com/content/7/S1/S5
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As malaria moves towards elimination and funding agencies require clearer feedback on progress, malaria reporting will need  to move towards more real-time and geographically-refined incidence reporting Figure 3
As malaria moves towards elimination and funding agencies require clearer feedback on progress, malaria reporting will need 
to move towards more real-time and geographically-refined incidence reporting. This will require the vast majority of malaria-
like fevers to be diagnosed using parasite-based diagnosis to confirm presence or absence of malaria parasites. At present, 
malaria reporting is at a relatively gross level. (a) Map of estimated malaria incidence per 1000 population, 2006 (Source: 
World Malaria Report, 2008), compared with some other diseases with well-developed case finding and reporting systems. (b) 
Map of wild poliovirus infections detected 29 Oct 2007 to 28 Oct 2008.Malaria Journal 2008, 7(Suppl 1):S5 http://www.malariajournal.com/content/7/S1/S5
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Conclusion
Sustained malaria control will depend on the global
capacity to accurately detect malaria and map its distribu-
tion. The specific detection of malaria parasites is now
possible even at the village level with high quality rapid
diagnostic tests. Driven by the extent of over-diagnosis
and misdiagnosis of malaria when syndromic approaches
are used, global efforts are underway to increase the utili-
zation of parasite-based diagnosis, and to ensure the qual-
ity of tests that are used. Elimination efforts will not only
increase the need for widespread RDT use, but may drive
the development of new tests with enhanced perform-
ance. Implementation of the Global Malaria Action Plan
[47], proposed regional initiatives towards elimination of
malaria, and the reductions in mortality from malarial
and non-malarial illness necessary to achieve Millennium
Development Goals will require an increased emphasis
on building systems for parasite detection as an integral
part of malaria case and programme management.
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